National Bank of Canada
GMAB icon

National Bank of Canada’s Genmab GMAB Stock Holding History

National Bank of Canada’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-350
Closed -$8.53K – 3034
2024
Q3 		$8.53K Buy
350
+85
+32% +$2.27K ﹤0.01% 2117
2024
Q2 		$6.58K Buy
265
+15
+6% +$425 ﹤0.01% 2214
2024
Q1 		$7.21K Buy
250
+124
+98% +$3.64K ﹤0.01% 2242
2023
Q4 		$4.05K Hold
126
– – ﹤0.01% 2343
2023
Q3 		$4.31K Sell
126
-54
-30% -$2.06K ﹤0.01% 2379
2023
Q2 		$6.84K Hold
180
– – ﹤0.01% 2273
2023
Q1 		$6.8K Sell
180
-1,939
-92% -$74.5K ﹤0.01% 2232
2022
Q4 		$89.8K Buy
2,119
+1,821
+611% +$75K ﹤0.01% 1597
2022
Q3 		$10K Sell
298
-100
-25% -$3.51K ﹤0.01% 2180
2022
Q2 		$13K Buy
398
+172
+76% +$5.57K ﹤0.01% 2192
2022
Q1 		$8K Buy
226
+72
+47% +$2.47K ﹤0.01% 2443
2021
Q4 		$6K Buy
+154
New +$6.42K ﹤0.01% 2494

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

National Bank of Canada's GMAB Position: Q4 2024 in Review

National Bank of Canada sold out of Genmab (GMAB) in Q4 2024, closing a stake of 350 shares — an estimated $8.53K sold.

National Bank of Canada first reported a position in GMAB in Q4 2021 and held it in 12 quarters. The position peaked at $89.8K in Q4 2022. 229 funds tracked by Wall St. Rank hold GMAB as of Q4 2024.

  • National Bank of Canada reported no remaining Genmab position as of Q4 2024 after selling out during the quarter.
  • National Bank of Canada sold 350 Genmab shares in Q4 2024, an estimated $8.53K.
  • National Bank of Canada first reported a position in Genmab in Q4 2021 and held it in 12 quarters.
  • National Bank of Canada's Genmab position peaked at $89.8K in Q4 2022.
  • 229 funds tracked by Wall St. Rank held Genmab as of Q4 2024.

Based on National Bank of Canada's 13F filing for Q4 2024, filed 12 Feb 2025.